Zwirska-Korczala K, Berdowska A, Jochem J, Sitkiewicz A, Birkner E, Polaniak R, Jedrzejowska-Szypułka H, Korzonek-Szlacheta I
Department of Physiology, Medical University of Silesia, Zabrze, Poland.
J Clin Pharm Ther. 2004 Apr;29(2):151-6. doi: 10.1111/j.1365-2710.2004.00547.x.
Activation of cell-mediated immunity by soluble interleukin-2 receptor alpha (sIL-2Ralpha) release is well documented. The aim of this study was to measure serum concentrations of sIL-2Ralpha in patients with autoimmune and non-autoimmune thyroid disorders in different stages of thyroid function, before and after administration of l-thyroxine (l-T4) and its discontinuation as well as before and during methimazole administration.
The study included 80 females: 16 with Graves' disease, 15 with Hashimoto's thyroiditis and subclinical hypothyroidism, 14 with Hashimoto's thyroiditis with fibrosis and clinical hypothyroidism, 20 after subtotal thyroidectomy following nodular non-toxic goitre and 15 healthy controls. Patients were examined at two different time points. Serum concentrations of sIL-2Ralpha were measured with the use of enzyme immunoassay technique.
Souble IL-2Ralpha serum concentration increased in patients with untreated Graves' disease and decreased after methimazole treatment. In Hashimoto's thyroiditis, the sIL-2Ralpha level was within the normal range, in Hashimoto's thyroiditis with clinical hypothyreosis it was low and after l-T4 administration it increased in both patient groups. After thyroidectomy, patients treated with l-T4, had increased levels of sIL-2Ralpha which decreased after discontinuation of therapy. There were a significant positive correlation between sIL-2Ralpha and free thyroxine in patients with (i). Graves' disease both before and after methimazole administration, (ii). Hashimoto's thyroiditis (with subclinical hypothyroidism) both before and after l-T4 therapy, (iii). Hashimoto's thyroiditis with fibrosis and (iv). overt hypothyroidism before l-T4 administration and in individuals during long-term l-T4 treatment (after subtotal thyroidectomy).
Serum sIL-2Ralpha concentration in autoimmune thyroid diseases depends on thyroid function. In both autoimmune and non-autoimmune thyroid diseases, thyroxine stimulates the release of sIL-2Ralpha.
可溶性白细胞介素 - 2受体α（sIL - 2Rα）释放激活细胞介导的免疫反应已有充分记录。本研究的目的是测量自身免疫性和非自身免疫性甲状腺疾病患者在甲状腺功能不同阶段、服用左旋甲状腺素（l - T4）前后及其停药后以及服用甲巯咪唑前后血清中sIL - 2Rα的浓度。
该研究纳入80名女性：16例格雷夫斯病患者、15例桥本甲状腺炎合并亚临床甲状腺功能减退患者、14例桥本甲状腺炎伴纤维化及临床甲状腺功能减退患者、20例结节性非毒性甲状腺肿甲状腺次全切除术后患者以及15名健康对照者。患者在两个不同时间点接受检查。采用酶免疫测定技术测量血清中sIL - 2Rα的浓度。
未经治疗的格雷夫斯病患者血清可溶性IL - 2Rα浓度升高，甲巯咪唑治疗后降低。在桥本甲状腺炎中，sIL - 2Rα水平在正常范围内，在临床甲状腺功能减退的桥本甲状腺炎中较低，服用l - T4后两组患者的该水平均升高。甲状腺切除术后，接受l - T4治疗的患者sIL - 2Rα水平升高，治疗中断后降低。在以下患者中，sIL - 2Rα与游离甲状腺素之间存在显著正相关：（i）服用甲巯咪唑前后的格雷夫斯病患者；（ii）l - T4治疗前后的桥本甲状腺炎（合并亚临床甲状腺功能减退）患者；（iii）伴有纤维化的桥本甲状腺炎患者；（iv）服用l - T4前的显性甲状腺功能减退患者以及长期接受l - T4治疗（甲状腺次全切除术后）的个体。
自身免疫性甲状腺疾病患者血清中sIL - 2Rα浓度取决于甲状腺功能。在自身免疫性和非自身免疫性甲状腺疾病中，甲状腺素均刺激sIL - 2Rα的释放。
